On Friday, The Department of Health and Human Services (HHS) released a list of 15 new prescription drugs that Medicare will negotiate lower prices for. Under the law, HHS is required to negotiate a specific number of drugs each year.
The list contains a number of drugs that older Americans use, including Janumet, which is used to treat diabetes, and Otezla, which is used to treat psoriatic arthritis. Ozempic, Rybelsus, and Wegovy – which are used to treat diabetes, cardiovascular disease, and obesity – are the most widely used drugs on the list, with about 2.2 million Medicare Part D beneficiaries taking them between November 2023 and October 2024. Trelegy Ellipta, used to treat Chronic Obstructive Pulmonary Disease, is the next most widely used drug, with about 1.2 million Part D enrollees using it for treatment.
“Lower prices for these drugs are needed and will save patients and taxpayers billions of dollars a year,” said Richard Fiesta, Executive Director of the Alliance. “We call on President-elect Trump and the next Administration to follow the law and negotiate a fair deal that puts the needs of patients first.”
Drug corporations will have until February 28, 2025, to indicate whether they will participate in the negotiations.
The post 15 New Drugs Selected for 2025 Medicare Price Negotiation appeared first on Retired Americans.